Investigators at the University of Michigan Comprehensive Cancer Center are using new MRI and CT techniques to target the prostate more precisely during radiation therapy and lower the risk of postoperative erectile dysfunction in men with prostate cancer, according to a report in the International Journal of Radiation Oncology Biology Physics (2005; 61:20-31).
Study links PARP inhibitors to increased risk of hematologic toxicity in mCRPC patients
November 23rd 2023A recently published study found an association between PARP inhibitor treatment and an increased risk of hematological adverse events, including anemia, thrombocytopenia, and neutropenia, in patients with metastatic castration-resistant prostate cancer.
Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer
June 22nd 2023"We're excited that the FDA approval of this radiotracer gives us yet more tools at our disposal to diagnose prostate cancer in all its forms, from early to late in the disease process," says David M. Schuster, MD, FACR.
Can remote patient monitoring help combat the staffing shortage?
November 22nd 2023"As more patients become interested in remote patient monitoring and case studies continue to show improved patient outcomes, practices must seek ways to integrate these tools into their workflows," writes Lucienne Marie Ide, MD, PhD.
2 Clarke Drive
Cranbury, NJ 08512